Skip to contentM
Milestone Pharmaceuticals Inc.
M
MISTMilestone Pharmaceuticals Inc. Q2 2026 · 10-Q
Revenue$559.00K$559.00K— vs Q2 2025 Net Income-$28.61M-$28.61MN/M vs Q2 2025 EPS Diluted-$0.21-$0.21N/M vs Q2 2025 Operating Income-$25,630,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Milestone Pharmaceuticals Inc. · CIK 1408443 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$22,740,000N/M Margins · derivedOperating margin-4585.0%
Net margin-5118.8%
ended Jun 30, 2026 · filed Aug 12, 2026 · 43 d after period end